Fibromyalgia neurobehavioral phenotypes remain distinct across varying levels of pharmacologic exposure: evidence from a multisite cohort ( n = 695)
CNS Spectrums · 2026 · 31 (1)
DOI: 10.1017/s1092852926101199 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift CNS Spectrums, online erschienen am 22.09.2026. Verfasst von Kevin V Hackshaw und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Medicine, The University of Texas at Austin Dell Medical School, Austin, USA. Hauptthemen laut MEDLINE: Fibromyalgia. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, National Institute of Neurological Disorders and Stroke.
Abstract (Originalsprache)
Objective
To determine whether pharmacologic exposure is associated with differences in fibromyalgia neurobehavioral phenotypes and whether medication burden explains symptom variability within phenotypes.
Methods
We analyzed a multisite cohort of 695 adults meeting fibromyalgia criteria, stratified into low- and high-impact phenotypes using a disability-based classification. Medication burden was quantified as total, centrally acting, and noncentrally acting medication counts. Between-phenotype differences and within-phenotype associations between medication burden and symptom severity were evaluated using nonparametric tests, Spearman correlation analyses, and multivariable linear regression models. Phenotypes were interpreted within the framework of centrally mediated neurobehavioral dysfunction.
Results
Participants classified within the high-impact neurobehavioral phenotype ( n = 175) demonstrated substantially greater symptom burden across fibromyalgia impact, central sensitization, depressive symptoms, pain severity, and vitality compared with low-impact participants ( n = 520). Centrally acting medication burden increased stepwise with phenotype severity, whereas noncentrally acting medication use did not differ between phenotypes. Within phenotypes, centrally acting medication burden showed weak and nonsignificant associations with symptom severity after adjustment for demographic covariates, explaining minimal variance in fibromyalgia impact ( R 2 < 0.05).
Conclusions
Fibromyalgia symptom phenotypes remained distinct across varying levels of pharmacologic exposure, and medication burden explained little within-phenotype symptom variability. Medication burden primarily reflects downstream clinical response to symptom severity rather than a determinant of phenotype organization. These findings support the use of stable multidimensional phenotypes for mechanistic, neurobiological, and stratified intervention studies in chronic pain and related central nervous system disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Rheumatology, Department of Medicine, The University of Texas at Austin Dell Medical School, Austin, USA.
- Department of Medicine, The University of Texas at Austin Dell Medical School, USA.
- Food Sciences and Technology, The Ohio State University, USA.
- Bioinformatics, The Ohio State University Wexner Medical Center, USA.
- Division of Immunology and Rheumatology, Department of Medicine, The Ohio State University Wexner Medical Center, Columbus, USA.
ORCID-Profile: Kevin V Hackshaw
Förderung
- NINDS NIH HHS
- National Institute of Neurological Disorders and Stroke
Zitieren
APA
Hackshaw, K. V., Osuna-Diaz, M. M., Sebastian, K. R., Nuguri, S. M., Castellvi, S. D., Yu, L., Giusti, M. M., Mikulik, Z., & Rodriguez-Saona, L. (2026). Fibromyalgia neurobehavioral phenotypes remain distinct across varying levels of pharmacologic exposure: evidence from a multisite cohort ( n = 695). CNS Spectrums, 31(1). https://doi.org/10.1017/s1092852926101199
Vancouver
Hackshaw KV, Osuna-Diaz MM, Sebastian KR, Nuguri SM, Castellvi SD, Yu L, et al. Fibromyalgia neurobehavioral phenotypes remain distinct across varying levels of pharmacologic exposure: evidence from a multisite cohort ( n = 695). CNS Spectrums. 2026;31(1). doi:10.1017/s1092852926101199
BibTeX
@article{Hackshaw2026,
author = {Hackshaw, Kevin V and Osuna-Diaz, Michelle M and Sebastian, Katherine R and Nuguri, Shreya Madhav and Castellvi, Silvia deLamo and Yu, Lianbo and Giusti, M Monica and Mikulik, Zhanna and Rodriguez-Saona, Luis},
title = {Fibromyalgia neurobehavioral phenotypes remain distinct across varying levels of pharmacologic exposure: evidence from a multisite cohort ( n = 695)},
journal = {CNS Spectrums},
year = {2026},
volume = {31},
number = {1},
doi = {10.1017/s1092852926101199}
}
EUVIMED